Accentia Biopharmaceuticals Announces Strategic Agreement with Baxter Healthcare Corporation

Published: Nov 29, 2010

TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI) today announced a strategic agreement with Baxter Healthcare Corporation (NYSE: BAX) to provide Accentia with the exclusive, worldwide right to purchase Baxter’s cyclophosphamide, which is marketed under the brand name Cytoxan®, for the treatment of designated autoimmune diseases including multiple sclerosis. Cyclophosphamide is the active drug used in Revimmune™ therapy, Accentia’s proprietary system-of-care being developed for the treatment of a broad range of autoimmune diseases.

Back to news